ROYALTY PHARMA

Syndax Pharmaceuticals reports Q3 2024 financial results, highlights clinical data for revumenib and Niktimvo™ at ASH Annual Meeting, and anticipates FDA approval and U.S. launch of revumenib for R/R KMT2Ar acute leukemia by December 26, 2024. The company expects topline data from AUGMENT-101 trial in 4Q24, potential sNDA filing in 1H25, and a $350 million royalty funding agreement for Niktimvo to fund through profitability.

Syndax Pharmaceuticals and Royalty Pharma announce a $350 million synthetic royalty funding agreement for Niktimvo™ (axatilimab-csfr), expected to fund Syndax through profitability with proforma cash approaching $800 million as of June 30. The agreement involves a 13.8% royalty on U.S. net sales of Niktimvo, with royalty payments ceasing upon reaching 2.35x the upfront payment. Niktimvo is a first-in-class anti-CSF-1R antibody approved for chronic graft-versus-host disease (GVHD) in the U.S., co-commercialized by Syndax and Incyte, with a planned U.S. launch by early Q1 2025.

Syndax Pharmaceuticals and Royalty Pharma announce a $350 million synthetic royalty funding agreement for Niktimvo™ (axatilimab-csfr), expected to fund Syndax through profitability and support upcoming launches and development of Niktimvo and revumenib.

Royalty Pharma enters $350 million synthetic royalty funding agreement with Syndax Pharmaceuticals for Niktimvo's U.S. net sales, receiving a 13.8% royalty until a 2.35x multiple is reached. The funding supports Niktimvo's launches and development, with Syndax's proforma cash nearing $800 million as of June 30. Niktimvo targets chronic graft-versus-host disease (GVHD).

Royalty Pharma plc and Syndax Pharmaceuticals announce a $350 million synthetic royalty funding agreement for Niktimvo (axatilimab-csfr), a first-in-class treatment for chronic graft-versus-host disease (GVHD). The agreement includes a 13.8% royalty on U.S. net sales of Niktimvo, with payments ceasing upon reaching a 2.35x multiple. The funds are expected to support Syndax through profitability and the launch of Niktimvo in the U.S. by early 2025.

Novo Nordisk invests in obesity and metabolic disease, partnering with Ascendis Pharma to use its delivery tech for long-acting GLP-1 drug and other diabetes/cardiovascular products. Novo could pay up to $285M for the GLP-1 drug and $77.5M per additional drug. Ascendis' tech aims to reduce dosing frequency, with Novo focusing on longer-acting agents to improve patient adherence.

Thermo Fisher's Oncomine receives FDA approval as a companion diagnostic for grade 2 IDH-mutant glioma, identifying patients eligible for Servier's Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition, with projected sales of $37m by 2030.

Thermo Fisher Scientific's Oncomine receives FDA approval for grade 2 IDH-mutant glioma, identifying patients eligible for Servier Pharmaceuticals' Voranigo treatment. Voranigo, a once-daily IDH1/IDH2 inhibitor, is the first targeted therapy for this condition. Oncomine, initially approved in 2017, is also used for NSCLC, CCA, MTC, and TC.